NASDAQ:OTICOtonomy Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Otonomy Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.27 +0.26 (+6.48 %) (As of 07/15/2020 04:00 PM ET) Add Compare Share Today's Range$4.17Now: $4.27▼$4.2950-Day Range$2.47MA: $3.25▼$4.2052-Week Range$1.53Now: $4.27▼$4.32Volume488,818 shsAverage Volume575,217 shsMarket Capitalization$131.81 millionP/E RatioN/ADividend YieldN/ABeta2.36 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a proprietary formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, a sustained-exposure formulation of small molecule otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOtonomy has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Otonomy has a potential upside of 110.8% from its current price of $4.27.Amount of Analyst CoverageOtonomy has only been the subject of 4 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesOtonomy has received 319 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOtonomy has received 308 “underperform” votes. (Add your “underperform” vote.)Community SentimentOtonomy has received 50.88% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote “Outperform” if you believe OTIC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOtonomy does not currently pay a dividend.Dividend GrowthOtonomy does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Otonomy insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 11.70% of the stock of Otonomy is held by insiders.Percentage Held by Institutions58.13% of the stock of Otonomy is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Otonomy are expected to grow in the coming year, from ($1.37) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Otonomy is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Otonomy is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOtonomy has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OTIC Previous Symbol CUSIPN/A CIK1493566 Webwww.otonomy.com Phone619-323-2200Debt Debt-to-Equity Ratio0.96 Current Ratio4.44 Quick Ratio4.44Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$600,000.00 Price / Sales219.69 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book3.26Profitability EPS (Most Recent Fiscal Year)($1.45) Net Income$-44,670,000.00 Net Margins-7,826.41% Return on Equity-98.90% Return on Assets-51.41%Miscellaneous Employees49 Outstanding Shares30,870,000Market Cap$131.81 million Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:OTIC Rates by TradingView Receive OTIC News and Ratings via Email Sign-up to receive the latest news and ratings for OTIC and its competitors with MarketBeat's FREE daily newsletter. Otonomy (NASDAQ:OTIC) Frequently Asked Questions How has Otonomy's stock been impacted by COVID-19 (Coronavirus)? Otonomy's stock was trading at $2.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OTIC shares have increased by 63.0% and is now trading at $4.27. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Otonomy? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Otonomy. When is Otonomy's next earnings date? Otonomy is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Otonomy. How were Otonomy's earnings last quarter? Otonomy Inc (NASDAQ:OTIC) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.02. The biopharmaceutical company had revenue of $0.16 million for the quarter. Otonomy had a negative return on equity of 98.90% and a negative net margin of 7,826.41%. View Otonomy's earnings history. What price target have analysts set for OTIC? 4 equities research analysts have issued 1-year price objectives for Otonomy's stock. Their forecasts range from $8.00 to $11.00. On average, they anticipate Otonomy's share price to reach $9.00 in the next year. This suggests a possible upside of 110.8% from the stock's current price. View analysts' price targets for Otonomy. Has Otonomy been receiving favorable news coverage? News coverage about OTIC stock has been trending somewhat positive recently, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Otonomy earned a news impact score of 1.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news about Otonomy. Who are some of Otonomy's key competitors? Some companies that are related to Otonomy include Catalyst Pharmaceuticals (CPRX), Syndax Pharmaceuticals (SNDX), Syros Pharmaceuticals (SYRS), Flexion Therapeutics (FLXN), Atreca (BCEL), Corbus Pharmaceuticals (CRBP), Crinetics Pharmaceuticals (CRNX), Prothena (PRTA), Viking Therapeutics (VKTX), Clovis Oncology (CLVS), Urogen Pharma (URGN), BioSpecifics Technologies (BSTC), AC Immune (ACIU), Mirum Pharmaceuticals (MIRM) and Emisphere Technologies (EMIS). View all competitors. What other stocks do shareholders of Otonomy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields (). Who are Otonomy's key executives? Otonomy's management team includes the following people: Dr. Jay B. Lichter, Co-Founder & Chairman (Age 57)Dr. David Allen Weber, Pres, CEO & Director (Age 59)Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 57)Mr. Robert Michael Savel II, Chief Technical Officer (Age 51)Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel What is Otonomy's stock symbol? Otonomy trades on the NASDAQ under the ticker symbol "OTIC." How do I buy shares of Otonomy? Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Otonomy's stock price today? One share of OTIC stock can currently be purchased for approximately $4.27. How big of a company is Otonomy? Otonomy has a market capitalization of $131.81 million and generates $600,000.00 in revenue each year. The biopharmaceutical company earns $-44,670,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Otonomy employs 49 workers across the globe. What is Otonomy's official website? The official website for Otonomy is www.otonomy.com. How can I contact Otonomy? Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected] This page was last updated on 7/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
